Form 4: Amgen SVP Derek Miller Receives Equity Grant

Amgen SVP of Human Resources Derek Miller was granted 910 restricted stock units and 5,938 stock options as part of an equity incentive plan.

Summary

• Derek Miller, SVP of Human Resources at Amgen, received a grant of 910 Restricted Stock Units (RSUs) on May 5, 2026.
• The reporting person was also granted 5,938 non-qualified stock options with an exercise price of $329.59.
• A total of 123 shares were withheld on May 6, 2026, to satisfy tax obligations related to the vesting of equity awards.
• Following these transactions, the reporting person holds 12,595 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding executive compensation, which carries no significant market sentiment implications.

Positives

• Equity grants align the interests of the SVP of Human Resources with long-term shareholder value.
• The vesting schedule of four equal annual installments encourages long-term retention of key management personnel.

Negatives

• The withholding of 123 shares for tax purposes represents a minor reduction in direct ownership.

Risks

• Future value of the granted stock options is dependent on the company's share price exceeding the $329.59 exercise price.

Future Outlook

The equity grants are subject to a four-year vesting schedule, with the first installment becoming exercisable or payable on May 5, 2027.

Management Comments

• The grants were issued pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan.

Industry Context

StockSavvy.ai notes that standard executive compensation packages in the biotechnology sector frequently utilize multi-year vesting RSU and option grants to ensure leadership stability and performance alignment.

Comparison to Industry Standards

• The use of four-year vesting schedules is consistent with standard corporate governance practices for large-cap pharmaceutical companies like Pfizer, Gilead, and AbbVie.

Stakeholder Impact

• Minimal impact on shareholders as the transaction represents standard executive compensation.

Next Steps

• Vesting of the first 25% of the RSU and option grants on May 5, 2027.

Key Dates

Keywords

Amgen, AMGN, Insider Trading, Form 4, Equity Incentive Plan, Stock Options, Restricted Stock Units